Literature DB >> 12504107

HVJ-envelope vector for gene transfer into central nervous system.

Munehisa Shimamura1, Ryuichi Morishita, Masayuki Endoh, Kazuo Oshima, Motokuni Aoki, Satoshi Waguri, Yasuo Uchiyama, Yasufumi Kaneda.   

Abstract

To overcome some problems of virus vectors, we developed a novel non-viral vector system, the HVJ-envelope vector (HVJ-E). In this study, we investigated the feasibility of gene transfer into the CNS using the HVJ-E both in vitro and in vivo. Using the Venus reporter gene, fluorescence could be detected in cultured rat cerebral cortex neurons and glial cells. In vivo, the reporter gene (Venus) was successfully transfected into the rat brain by direct injection into the thalamus, intraventricular injection, or intrathecal injection, without inducing immunological change. When the vector was injected after transient occlusion of the middle cerebral artery, fluorescence due to EGFP gene or luciferase activity could be detected only in the injured hemisphere. Finally, luciferase activity was markedly enhanced by the addition of 50 U/ml heparin (P<0.01). Development of efficient HVJ-E for gene transfer into the CNS will be useful for research and clinical gene therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12504107     DOI: 10.1016/s0006-291x(02)02807-3

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Transfection of neuroprogenitor cells with iron nanoparticles for magnetic resonance imaging tracking: cell viability, differentiation, and intracellular localization.

Authors:  Sosuke Miyoshi; Jennifer A Flexman; Donna J Cross; Kenneth R Maravilla; Yongmin Kim; Yoshimi Anzai; Junko Oshima; Satoshi Minoshima
Journal:  Mol Imaging Biol       Date:  2005 Jul-Aug       Impact factor: 3.488

2.  cAMP-response element (CRE)-mediated transcription by activating transcription factor-4 (ATF4) is essential for circadian expression of the Period2 gene.

Authors:  Satoru Koyanagi; Ahmed M Hamdan; Michiko Horiguchi; Naoki Kusunose; Akinori Okamoto; Naoya Matsunaga; Shigehiro Ohdo
Journal:  J Biol Chem       Date:  2011-07-18       Impact factor: 5.157

3.  Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2.

Authors:  Stefan Fichtner-Feigl; Masaki Terabe; Atsushi Kitani; Cheryl A Young; Ivan Fuss; Edward K Geissler; Hans-Jürgen Schlitt; Jay A Berzofsky; Warren Strober
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

4.  Percutaneous nonviral delivery of hepatocyte growth factor in an osteotomy gap promotes bone repair in rabbits: a preliminary study.

Authors:  Hidenori Matsubara; Hiroyuki Tsuchiya; Koji Watanabe; Akihiko Takeuchi; Katsuro Tomita
Journal:  Clin Orthop Relat Res       Date:  2008-09-24       Impact factor: 4.176

5.  Magnetically targeted viral envelopes: a PET investigation of initial biodistribution.

Authors:  Jennifer A Flexman; Donna J Cross; Barbara L Lewellen; Sosuke Miyoshi; Yongmin Kim; Satoshi Minoshima
Journal:  IEEE Trans Nanobioscience       Date:  2008-09       Impact factor: 2.935

6.  Complexation design of cationized gelatin and molecular beacon to visualize intracellular mRNA.

Authors:  Sho Takehana; Yuki Murata; Jun-Ichiro Jo; Yasuhiko Tabata
Journal:  PLoS One       Date:  2021-01-25       Impact factor: 3.240

Review 7.  Virosome presents multimodel cancer therapy without viral replication.

Authors:  Kotaro Saga; Yasufumi Kaneda
Journal:  Biomed Res Int       Date:  2013-12-04       Impact factor: 3.411

8.  IL-13 signaling via IL-13Rα2 triggers TGF-β1-dependent allograft fibrosis.

Authors:  Stefan M Brunner; Gabriela Schiechl; Rebecca Kesselring; Maria Martin; Saidou Balam; Hans J Schlitt; Edward K Geissler; Stefan Fichtner-Feigl
Journal:  Transplant Res       Date:  2013-10-22

Review 9.  Oncolytic Sendai virus-based virotherapy for cancer: recent advances.

Authors:  Kotaro Saga; Yasufumi Kaneda
Journal:  Oncolytic Virother       Date:  2015-10-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.